Price
$137.85-27.97%Social Signal Score
Analyst Ratings
13 analysts52-week range
- Last close
- $137.85
- Off 52w high
- -80.7%
- 200-day average
- $157.51
- vs 200-day
- -12.5%
Revenue
$3.44B+82.86%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian J. Choi
- Sector
- Industrials
- Industry
- Rental & Leasing Services
- Employees
- 21,000
- Beta
- 2.02
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.60
Financials
Revenue
$3.44B+82.9%Net Income
$183.00MEBITDA
$1.40B+149.8%Free Cash Flow
$-1.11B-186.4%EPS (diluted)
$5.15Shares Outstanding (diluted)
35.60M-59.3%Operating Expenses
$398.00MCash & Debt
$561.00MReturn of Capital
$2.00MRevenue by Segment (annual)
$202.00MDividend per Share
$10.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.65B | $-889.00M | $-25.26 |
| 2024 | $11.79B | $-1.82B | $-51.23 |
| 2023 | $12.01B | $1.63B | $42.61 |
| 2022 | $11.99B | $2.76B | $58.44 |
| 2021 | $9.31B | $1.28B | $19.80 |
| 2020 | $5.40B | $-684.00M | $-9.70 |
| 2019 | $9.17B | $302.00M | $4.02 |
| 2018 | $9.12B | $165.00M | $2.08 |
| 2017 | $8.85B | $361.00M | $4.32 |
| 2016 | $8.66B | $163.00M | $1.78 |
| 2015 | $8.50B | $313.00M | $3.02 |
| 2014 | $8.48B | $245.00M | $2.32 |
| 2013 | $7.94B | $16.00M | $0.15 |
| 2012 | $7.36B | $290.00M | $2.72 |
Valuation
CARhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30+0.00%Social Signal Score
Mentions (45)
- Newsglobenewswire.com·2d ago·Negative
Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access SOUTH SAN FRANCISCO, Calif., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the 68th American Society of Hematology (ASH) Annua…
View source ↗ - Newsglobenewswire.com·11d ago·Neutral
Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates
View source ↗ - News (Marketaux)seekingalpha.com·13d ago·Neutral
Avis Budget Group, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CAR) 2026-11-09 Avis Budget Group, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CAR) 2026-11-09
View source ↗ - News (RSS)seekingalpha·13d ago·Neutral
Avis Budget Group, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
HSS Study Highlights Potential for CAR T-Cell Therapy to Transform Lupus Treatment ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS). Known as chimeric antigen receptor (CAR) T-cell therapy, the approach is increasingly being investigated for the treatment of systemic lupus erythematosus…
View source ↗ - Newszacks.com·16d ago·Negative
Avis Budget Stock Appreciates 10% Despite Earnings Miss in Q3 CAR shares jump 10.2% despite a Q3 earnings miss, as record fleet utilization, improved cash flow and expectations of Q4 EBITDA recovery draw attention.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two prior lines of therapy.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Avis Budget Group, Inc. (CAR) Q3 2026 Earnings Call Transcript Avis Budget Group, Inc. ( CAR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants David Calabria - Treasurer & Senior VP of Corporate Finance Brian Choi - Chief Executive Officer Daniel Cunha - Executive VP & CFO Conference Call Participants John Healy - Northcoast Research Partners, LLC Stephanie Benjamin Moore - Jefferies LLC, Research Division Christopher Stathoulopoulos - Susquehanna Financial Group, LLLP, R…
View source ↗ - Newsmarketbeat.com·18d ago·Negative
What Avis Budget Group (CAR) Said on Its Q3 Earnings Call Avis Budget Group NASDAQ: CAR reported third-quarter adjusted EBITDA of $513 million, down 8% from a year earlier and about $50 million below the company's prior expectations, as weaker travel demand in August pressured rental volume, revenue mix and operating leverage.
View source ↗ - Newsprnewswire.com·18d ago·Neutral
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham…
View source ↗ - Newszacks.com·19d ago·Negative
Compared to Estimates, Avis Budget (CAR) Q3 Earnings: A Look at Key Metrics The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·19d ago·Negative
Avis Budget Group (CAR) Misses Q3 Earnings Estimates Avis Budget Group (CAR) came out with quarterly earnings of $5.15 per share, missing the Zacks Consensus Estimate of $8.47 per share. This compares to earnings of $10.11 per share a year ago.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona.…
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gravis are expected in Q1 2027, with a potential BLA filing in mid-2027. RNAC is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach via a strategic WestGene licensin…
View source ↗ - Newsprnewswire.com·27d ago·Neutral
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to date Patients in fifth cohort received 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., Oct. 26, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Co…
View source ↗ - Newsaccessnewswire.com·38d ago·Neutral
…nd PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expected in Q2 2027 FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic…
View source ↗ - Newsglobenewswire.com·38d ago·Negative
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech's in vivo cell engineering platform BRIDG…
View source ↗ - Newsglobenewswire.com·39d ago·Negative
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer a…
View source ↗ - Newsprnewswire.com·40d ago·Neutral
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ov…
View source ↗ - Newsprnewswire.com·48d ago·Neutral
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the tr…
View source ↗ - Newszacks.com·52d ago·Positive
Can Higher Fleet Utilization Boost Avis Budget's Profitability? CAR's stronger utilization and lower fleet costs lift second-quarter profits despite fewer vehicles and softer rental volumes.
View source ↗ - Newsglobenewswire.com·52d ago·Neutral
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell The…
View source ↗ - Newsprnewswire.com·52d ago·Neutral
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment …
View source ↗ - Newsglobenewswire.com·52d ago·Negative
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFA…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Portnoy Law Firm Announces Class Action on Behalf of Avis Budget Group, Inc. Investors LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Avis Budget Group, Inc., (“Avis” or the "Company") (NASDAQ: CAR) investors of a class action on behalf of investors that bought securities between February 20, 2025 - April 21, 2026, inclusive (the “Class Period”).
View source ↗ - Newsglobenewswire.com·59d ago·Negative
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million.
View source ↗ - Newsglobenewswire.com·66d ago·Neutral
Avis aux médias : Des policiers de la Saskatchewan seront honorés dans le cadre des Prix policiers de la famille Van de Vorst de MADD Canada pour leurs efforts visant à contrer la conduite avec capacités affaiblies OAKVILLE, Ontario, 17 sept. 2026 (GLOBE NEWSWIRE) -- MADD Canada invite les médias à assister à deux cérémonies spéciales en l'honneur des policiers de la Saskatchewan pour leurs efforts extraordinaires visant à mettre fin à la conduite avec capacités affaiblies, à assurer la sécurité
View source ↗ - Newsglobenewswire.com·67d ago·Positive
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-s…
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
View source ↗ - Newsglobenewswire.com·74d ago·Neutral
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf ant…
View source ↗ - Newsglobenewswire.com·75d ago·Negative
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent
View source ↗ - Newsgurufocus.com·83d ago·Negative
CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit Against Pentwater Capital Management LP P
View source ↗ - News (RSS)investing·83d ago·Positive
Avis Budget Group stock analysis: technicals, key levels, and what’s driving Monday’s rally
View source ↗ - Newsseekingalpha.com·86d ago·Negative
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? Cema-cel produced MRD clearance in 58.3% of treated patients versus 16.7% under observation. The 97.7% median ctDNA reduction by day 45 shows substantial early biological activity. FDA RMAT and Fast Track designations support the development strategy but do not prove durable efficacy.
View source ↗ - Newszacks.com·90d ago·Positive
Here's Why Investors Should Hold Avis Budget in Their Portfolios Now CAR shares have jumped 57.8% in six months as rental demand, tech partnerships and buybacks support growth despite liquidity risks.
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd.
View source ↗ - 4chan /biz/biz·95d ago·Neutral
>>62609530 Is there an Avis rent a car general? I think GME was a psyop at this point.
View source ↗ - Newsseekingalpha.com·100d ago·Neutral
Adicet Bio: A Cheap Gamma Delta T-Cell Play Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50% complete renal response and clean safety, supporting the curative CAR-T thesis versus chronic biologics. The upcoming 3Q 2026 readout on 22 patients is a binary catalyst; durability and long-term remission are critical for upside realization.
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027
View source ↗ - Newsglobenewswire.com·101d ago·Neutral
…s Founder, Chief Executive Officer (“CEO”), and Chief Investment Officer Matthew Halbower (“Halbower”) and on behalf of investors in Avis Budget Group, Inc. (NASDAQ: CAR). This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Avis securities between February 20, 2025 and April 21, 2026, both dates inclusive (the “Class Period”).
View source ↗ - News (RSS)bbc·101d ago·Positive
French ambassador to CAR accused of misconduct at official residence faces disciplinary action The accusations against Bruno Foucher prompted investigations into a potential security breach.
View source ↗ - Newsprnewswire.com·106d ago·Negative
RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias /PRNewswire/ -- RiboX Therapeutics Ltd. ("RiboX"), a global clinical-stage biotechnology company pioneering fully engineered circular RNA (circRNA)
View source ↗ - 4chan /biz/biz·107d ago·Neutral
>>62572824 >he doesn't know about CAR
View source ↗ - 4chan /biz/biz·107d ago·Positive
>>62571966 >HTZ will probably end the day at $3 why not go higher the volume looks ripe for a crazy run up like CAR
View source ↗ - 4chan /biz/biz·107d ago·Positive
>>62571508 or it could squeeze like CAR earlier this year it's a gamble
View source ↗
Earnings
Wed, Feb 17(in 3 months)
Consensus estimate $-0.79 per share
Typical surprise -52.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 3$5.15 vs $8.01miss
- Tue, Jul 28$0.98 vs $2.05miss
- Wed, Apr 29$-8.01 vs $-6.82miss
- Wed, Feb 18$-6.53 vs $-0.29miss
- Mon, Oct 27$10.11 vs $8.11beat
- Tue, Jul 29$0.10 vs $2.02miss
Estimates and results for CAR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CAR officers and directors.
- Bought
- —
- Sold
- $257.5m
0 trades
89 trades
- Linnen Edward Psold
- Linnen Edward Psold
- Linnen Edward Psold
- Linnen Edward Psold
- Linnen Edward Psold
- Lurie Glennsold
- Lurie Glennsold
- Lurie Glennsold
11 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
